药明生物(02269)今日盘中股价出现大幅下挫，跌幅达5.01%，引起了市场关注。
消息面上，美银证券发表研究报告，将药明生物的目标价由47港元下调至39.5港元，评级为“中性”。该行同时将公司2026年至2028年的收入预测下调了4%至8%。此外，瑞银也在其研报中下调了药明生物今明两年的每股盈利预测4%至5%，并将目标价由51.6港元微降至49.3港元。尽管瑞银维持“买入”评级，但多家大行相继下调财务预测及目标价，可能引发了投资者的担忧情绪。
与此同时，中金公司发布报告上调了药明生物的目标价至48港元，并维持“跑赢行业”评级。然而，市场似乎对下调盈利前景的报告反应更为敏感，导致了股价在交易时段的显著下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.